Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD)”

2 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 2 of 2 results

Not applicableNo Longer AvailableNCT02822495
What this trial is testing

Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies

Who this might be right for
Epstein-Barr Virus (EBV) InfectionsLymphoproliferative DisordersEBV+ Associated Lymphoma+9 more
Atara Biotherapeutics
Testing effectiveness (Phase 2)Looking for participantsNCT04554914
What this trial is testing

Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases

Who this might be right for
Epstein-Barr Virus (EBV)-Associated DiseasesEBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD)EBV+ Lymphoproliferative Disease With Acquired (Non-congenital) Immunodeficiency (EBV+ AID LPD)+8 more
Pierre Fabre Medicament
190